Accelerate Book Value Per Share from 2010 to 2025

AXDX Stock

USD 0.86 0.02 2.27%

Accelerate Diagnostics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Accelerate Diagnostics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(2.40)

Current Value

(2.28)

Quarterly Volatility

11.11672248

Credit Downgrade

Yuan Drop

Covid

Check Accelerate Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Accelerate Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Selling General Administrative of 16.3 M or Total Revenue of 12.3 M, as well as many indicators such as Price To Sales Ratio of 2.27, Dividend Yield of 2.0E-4 or Days Sales Outstanding of 60.38. Accelerate financial statements analysis is a perfect complement when working with Accelerate Diagnostics Valuation or Volatility modules.

Check out the analysis of Accelerate Diagnostics Correlation against competitors.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Latest Accelerate Diagnostics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Accelerate Diagnostics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Accelerate Diagnostics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Accelerate Diagnostics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (2.23) X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Accelerate Book Value Per Share Regression Statistics

	Arithmetic Mean	6.42
	Coefficient Of Variation	173.06
	Mean Deviation	9.40
	Median	10.53
	Standard Deviation	11.12
	Sample Variance	123.58
	Range	40.7753
	R-Value	(0.60)
	Mean Square Error	85.44
	R-Squared	0.35
	Significance	0.01
	Slope	(1.39)
	Total Sum of Squares	1,854

Accelerate Book Value Per Share History

	2025	-2.28
	2024	-2.4
	2023	-1.59
	2022	-2.71
	2021	-5.68
	2020	-11.21
	2019	-1.35

Other Fundumenentals of Accelerate Diagnostics

Tangible Book Value Per Share

Accelerate Diagnostics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Treasury Stock	Property Plant Equipment	Intangible Assets	Good Will	Short Term Debt	Net Tangible Assets	Long Term Debt	Short Term Investments	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.47	0.02	-0.09	0.03	0.24	0.42	1.0	-0.53	-0.2	-0.24	0.43	-0.44	-0.5	-0.12	0.43	0.49	0.82	0.27	0.62	-0.12	0.46	0.41	0.22
Total Stockholder Equity	0.47		-0.82	0.64	-0.34	-0.53	-0.6	0.51	-0.05	-0.43	0.68	-0.38	-0.03	-0.07	-0.32	0.98	-0.49	0.45	-0.49	-0.12	-0.32	0.66	0.66	0.07
Net Debt	0.02	-0.82		-0.68	0.23	0.73	0.86	-0.02	-0.16	0.33	-0.84	0.55	-0.13	-0.12	0.23	-0.84	0.81	0.14	0.62	0.43	0.22	-0.35	-0.37	0.06
Retained Earnings	-0.09	0.64	-0.68		-0.84	-0.82	-0.73	-0.05	0.52	-0.76	0.89	-0.92	0.44	0.47	-0.47	0.6	-0.54	0.02	-0.98	-0.72	-0.46	0.78	0.8	0.14
Accounts Payable	0.03	-0.34	0.23	-0.84		0.61	0.36	0.01	-0.54	0.8	-0.61	0.81	-0.45	-0.47	0.54	-0.27	0.13	-0.2	0.84	0.56	0.55	-0.81	-0.84	-0.23
Net Receivables	0.24	-0.53	0.73	-0.82	0.61		0.76	0.19	-0.31	0.59	-0.86	0.79	-0.29	-0.34	0.35	-0.54	0.63	0.19	0.8	0.62	0.34	-0.46	-0.5	-0.03
Total Liab	0.42	-0.6	0.86	-0.73	0.36	0.76		0.38	-0.42	0.25	-0.92	0.76	-0.36	-0.38	0.23	-0.62	0.95	0.28	0.74	0.67	0.22	-0.25	-0.29	0.13
Total Current Assets	1.0	0.51	-0.02	-0.05	0.01	0.19	0.38		-0.51	-0.22	-0.2	0.39	-0.44	-0.48	-0.14	0.47	0.45	0.82	0.23	0.58	-0.14	0.49	0.45	0.21
Common Stock	-0.53	-0.05	-0.16	0.52	-0.54	-0.31	-0.42	-0.51		-0.31	0.44	-0.68	0.65	0.47	-0.17	-0.07	-0.34	-0.36	-0.63	-0.65	-0.17	0.24	0.26	0.02
Current Deferred Revenue	-0.2	-0.43	0.33	-0.76	0.8	0.59	0.25	-0.22	-0.31		-0.48	0.63	-0.31	-0.19	0.24	-0.33	0.09	-0.18	0.72	0.43	0.25	-0.83	-0.77	-0.52
Treasury Stock	-0.24	0.68	-0.84	0.89	-0.61	-0.86	-0.92	-0.2	0.44	-0.48		-0.85	0.37	0.39	-0.39	0.7	-0.8	-0.11	-0.86	-0.66	-0.37	0.5	0.54	0.0
Property Plant Equipment	0.43	-0.38	0.55	-0.92	0.81	0.79	0.76	0.39	-0.68	0.63	-0.85		-0.57	-0.59	0.37	-0.34	0.61	0.23	0.98	0.86	0.37	-0.56	-0.59	-0.09
Intangible Assets	-0.44	-0.03	-0.13	0.44	-0.45	-0.29	-0.36	-0.44	0.65	-0.31	0.37	-0.57		0.56	-0.15	-0.03	-0.29	-0.28	-0.52	-0.53	-0.15	0.21	0.22	0.02
Good Will	-0.5	-0.07	-0.12	0.47	-0.47	-0.34	-0.38	-0.48	0.47	-0.19	0.39	-0.59	0.56		-0.16	-0.05	-0.31	-0.31	-0.55	-0.56	-0.15	0.21	0.23	0.01
Short Term Debt	-0.12	-0.32	0.23	-0.47	0.54	0.35	0.23	-0.14	-0.17	0.24	-0.39	0.37	-0.15	-0.16		-0.31	-0.08	-0.2	0.43	0.21	1.0	-0.45	-0.64	0.53
Net Tangible Assets	0.43	0.98	-0.84	0.6	-0.27	-0.54	-0.62	0.47	-0.07	-0.33	0.7	-0.34	-0.03	-0.05	-0.31		-0.53	0.41	-0.45	-0.1	-0.3	0.58	0.59	0.0
Long Term Debt	0.49	-0.49	0.81	-0.54	0.13	0.63	0.95	0.45	-0.34	0.09	-0.8	0.61	-0.29	-0.31	-0.08	-0.53		0.38	0.57	0.59	-0.09	-0.04	-0.03	0.03
Short Term Investments	0.82	0.45	0.14	0.02	-0.2	0.19	0.28	0.82	-0.36	-0.18	-0.11	0.23	-0.28	-0.31	-0.2	0.41	0.38		0.13	0.47	-0.2	0.56	0.53	0.14
Capital Surpluse	0.27	-0.49	0.62	-0.98	0.84	0.8	0.74	0.23	-0.63	0.72	-0.86	0.98	-0.52	-0.55	0.43	-0.45	0.57	0.13		0.82	0.43	-0.69	-0.71	-0.1
Long Term Debt Total	0.62	-0.12	0.43	-0.72	0.56	0.62	0.67	0.58	-0.65	0.43	-0.66	0.86	-0.53	-0.56	0.21	-0.1	0.59	0.47	0.82		0.2	-0.31	-0.33	-0.04
Short Long Term Debt	-0.12	-0.32	0.22	-0.46	0.55	0.34	0.22	-0.14	-0.17	0.25	-0.37	0.37	-0.15	-0.15	1.0	-0.3	-0.09	-0.2	0.43	0.2		-0.45	-0.64	0.52
Net Invested Capital	0.46	0.66	-0.35	0.78	-0.81	-0.46	-0.25	0.49	0.24	-0.83	0.5	-0.56	0.21	0.21	-0.45	0.58	-0.04	0.56	-0.69	-0.31	-0.45		0.97	0.3
Net Working Capital	0.41	0.66	-0.37	0.8	-0.84	-0.5	-0.29	0.45	0.26	-0.77	0.54	-0.59	0.22	0.23	-0.64	0.59	-0.03	0.53	-0.71	-0.33	-0.64	0.97		0.11
Capital Stock	0.22	0.07	0.06	0.14	-0.23	-0.03	0.13	0.21	0.02	-0.52	0.0	-0.09	0.02	0.01	0.53	0.0	0.03	0.14	-0.1	-0.04	0.52	0.3	0.11

Click cells to compare fundamentals

About Accelerate Diagnostics Financial Statements

Accelerate Diagnostics investors use historical fundamental indicators, such as Accelerate Diagnostics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Accelerate Diagnostics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	(2.40)	(2.28)
Tangible Book Value Per Share	(2.40)	(2.28)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC